logo 03 logo 05 logo 07

Press release

Inserm Transfert and MassBio announce a partnership to foster innovation, technology transfer and entrepreneurship between France and Massachusetts (USA).

Learn more


Press release

QIAGEN Marseille acquires exclusive rights from Inserm Transfert SA and Inserm on HSP110 mutations for colorectal cancer.

 

Learn more


Press release

GlaxoSmithKline (GSK), Imagine Institute and Inserm Transfert have agreed a collaborative partnership to discover and develop medicines with the potential to treat Netherton Syndrome, a rare, genetically inherited, severe skin disorder

Inserm Transfert Initiative

“Investments for the future” programme: Fonds National d’Amorçage's first investment is in Inserm Transfert Initiative, a seed capital company specialising in life sciences and healthcare

Four granted under the FP7 call of proposals

By Plimun Web Design



INSERM TRANSFERT
Paris Biopark - 7 rue Watt - 75013 PARIS
Phone  +33 (0)1 55 03 01 00
Fax +33 (0)1 55 03 01 60
contact@inserm-transfert.fr